Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06214481
Status:
COMPLETED
Last Update Posted:
2024-06-04
First Post:
2024-01-10
Brief Title:
A Study to Evaluate Rocatinlimab AMG 451 in Healthy Chinese Participants
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 1 Open-label Single-dose Study to Evaluate the Pharmacokinetics Safety and Tolerability of Rocatinlimab AMG 451 Administered Subcutaneously in Healthy Chinese Subjects
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to evaluate the pharmacokinetics of rocatinlimab after single subcutaneous SC administration in healthy Chinese participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None